Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. - Wikidata - wikimedia - TriplyDB

Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.

Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.

http://www.wikidata.org/entity/Q34583341

about

Ultra-long acting insulin versus long-acting insulin for type 1 diabetes mellitus Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review Concentrated insulins: the new basal insulins Fatty acids as therapeutic auxiliaries for oral and parenteral formulations Treating type 1 diabetes: from strategies for insulin delivery to dual hormonal control Clinical utility of insulin and insulin analogs.Insulin degludec in Japanese patients with type 1 diabetes mellitus: A randomized controlled trial.Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial.Prediction of nocturnal hypoglycemia unawareness by fasting glucose levels or post-breakfast glucose fluctuations in patients with type 1 diabetes receiving insulin degludec: A pilot study.Can a new ultra-long-acting insulin analogue improve patient care? Investigating the potential role of insulin degludec.Treat-to-target trials: uses, interpretation and review of concepts.Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial.Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical The beneficial effect of insulin degludec on nocturnal hypoglycaemia and insulin dose in type 1 diabetic patients: a systematic review and meta-analysis of randomised trials.Effects of insulin degludec and insulin glargine on day-to-day fasting plasma glucose variability in individuals with type 1 diabetes: a multicentre, randomised, crossover study.Uncovering undetected hypoglycemic events Insulin analogs for the treatment of diabetes mellitus: therapeutic applications of protein engineering.Improved health status with insulin degludec compared with insulin glargine in people with type 1 diabetes Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial.Insulin degludec requires lower bolus insulin doses than does insulin glargine in Japanese diabetic patients with insulin-dependent state.Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.Design of non-standard insulin analogs for the treatment of diabetes mellitus Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes?Insulin degludec improves health-related quality of life (SF-36® ) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials.Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension Future of newer basal insulin Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials.Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study.A novel insulin combination of insulin degludec and insulin aspart achieves a more stable overnight glucose profile than insulin glargine: results from continuous glucose monitoring in a proof-of-concept trial.Insulin degludec: a significant advancement in ultralong-acting Basal insulin.Insulin degludec: pharmacokinetics in patients with renal impairment.Using albumin to improve the therapeutic properties of diabetes treatments.Improving the treatment experience for patients with type 2 diabetes: role of the nurse practitioner.Evolution of insulin development: focus on key parameters.Efficacy and safety of ultra-long-acting insulin degludec.Insulin degludec: overview of a novel ultra long-acting basal insulin.Insulin degludec: a novel basal insulin analogue.Newer insulin analogs: advances in basal insulin replacement.Insulin therapies: Current and future trends at dawn.

P2860

Q24194881-28B91741-AFB2-4BB8-A02B-4B27C857CC9D Q24624156-F61ED0A4-1287-4B03-B407-0BF33F3C578F Q24630395-B04989B1-8BE8-4058-8450-287513C4DE35 Q26750438-D17EA93D-2CDE-4521-838F-68F4D7E3F391 Q26828805-D060E56D-0E30-49EA-9EFF-339957649C34 Q26853250-E1FE8FA2-33CD-4AEE-8EA8-5C3546907CC3 Q30429358-FAE565E0-DDE4-4CFB-99DB-88FAF9EC9E0A Q33603473-6EE03C2D-99F9-46C9-9F31-12D6085BFFD8 Q33607759-2A487AC7-D2FC-41C3-8850-943FB4758084 Q33879458-131F3316-6702-4858-BF68-794CAD76C495 Q34311240-F86590EB-6B92-4C9A-A9B2-3B94EF0752BC Q34540987-1670C8AC-556E-4A97-A5E6-8D038D9120BD Q34543035-D9D0B3AF-0EAA-4DB4-9974-7C88DD7F5929 Q34691408-84E0ED71-2D82-4797-866B-F82B225AB5DE Q35457098-BFC791E3-E8B3-45AE-BD1F-077CD205250D Q35921474-C3E01F7B-30CA-477A-8284-E10D2225621D Q35922100-9B096DD5-68BC-4B59-B457-9FDF67C18BE9 Q35988978-0C88A585-12FF-4893-9057-2480F669B250 Q36097341-D4E90CCB-B6E9-4E7F-89B8-9538040B20EE Q36103732-C7D38C11-369B-4E63-9CDC-86D0F69790E7 Q36158944-8B07BE83-E156-49E8-A6F3-13281E34FD64 Q36334638-A3510443-12A5-4E1B-A417-9CEFDBB73DC8 Q36374363-9BC8AE8F-74C0-4816-8AB5-039DF5E154BB Q36554243-A0D16B45-87CA-4347-AA26-1269E7C87DD8 Q36629179-B5F998DA-0A4C-4AC9-AF07-28468005906A Q36730246-739076C3-85F3-4F33-98AA-538CC551FF9E Q36930701-8CCC50EC-D2A4-4AB0-B663-5EBF057C3A08 Q37119978-E4E5E66C-6A20-4AF9-8D73-1F5B18495E30 Q37374117-FA27AA2D-D47D-4DA6-A18D-3DEFF21AA666 Q37421683-9538C055-EF69-4DFC-A14E-0D2B03751FB3 Q37468486-B2516095-5CE9-4390-A968-A8EF57C48995 Q37506526-5010A879-5DFF-4839-BF49-512FEE5261EA Q37910976-EBEF445E-3725-4BFE-A17A-6EDCA81A1F5A Q38008007-A39C84EB-80AC-4EF3-8C17-8D2BB8AFF39E Q38030454-6FFE3278-178E-4BF6-B2F1-244A7829330F Q38059486-1863C239-6C2C-4A9B-9B6B-3470D918C40A Q38067424-C2C91623-2320-42D9-8152-E3404AF353D0 Q38079527-457F01CA-F01D-49B1-9272-1E5DAA145CC7 Q38085332-69958AF4-8FEE-4B78-917A-D8D2B3D6BA7E Q38089594-63756FD8-07A7-462A-8A69-50DD5AE65122

P2860

Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.

http://www.wikidata.org/entity/Q34583341

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Insulin degludec in type 1 dia ...... ompared with insulin glargine.

@ast

Insulin degludec in type 1 dia ...... ompared with insulin glargine.

@en

Insulin degludec in type 1 dia ...... ompared with insulin glargine.

@nl

type

label

Insulin degludec in type 1 dia ...... ompared with insulin glargine.

@ast

Insulin degludec in type 1 dia ...... ompared with insulin glargine.

@en

Insulin degludec in type 1 dia ...... ompared with insulin glargine.

@nl

prefLabel

Insulin degludec in type 1 dia ...... ompared with insulin glargine.

@ast

Insulin degludec in type 1 dia ...... ompared with insulin glargine.

@en

Insulin degludec in type 1 dia ...... ompared with insulin glargine.

@nl

P1433

Q34583341-F59555B7-3D29-420A-843F-D1CA15670F53

P1476

Q34583341-E69B97DD-3D66-4086-93FD-8508F3B97F60

P2093

Q34583341-5929E81C-EDB7-42C7-8AAA-5E06DC46A1E6

Q34583341-63B777D2-8A2C-42B7-8C46-A482C3561705

Q34583341-79B5F454-BA83-4471-9A08-27EB2B2D15CE

Q34583341-7C25FFE1-4594-44E7-A330-8C2C6A0044DF

Q34583341-A0F0264C-EE67-44B4-A76E-36981A58D907

Q34583341-A8C2EB0E-00F8-45D9-93AD-F28A9AC35B53

Q34583341-B925D5D5-8A7B-4F07-9C3C-1B7B2DDE35B0

Q34583341-DDC33A25-5BDD-4B63-97D0-78B8D0B755A9

Q34583341-FDCE688E-04E6-45D0-9729-EDF68FAEFBC0

P2860

Q34583341-281380AB-A727-4A39-BFCB-CF0EFCC644E4

Q34583341-2C381840-E13F-48F5-9190-6501C9166665

Q34583341-3B2C126F-F2C3-45BB-BF98-EFE9CFAB101D

Q34583341-4E0946C5-AE89-4990-9E67-5CFD79AB2502

Q34583341-51125BE8-E1B0-447F-8654-926EAAEE9F50

Q34583341-62F8A50E-B76C-4D8F-B135-9035C7193EF4

Q34583341-8968BEE7-3BB3-4E42-804A-CC48FF2D6641

Q34583341-9E30A88C-6CC9-4617-A0C8-C11FBFE8883D

Q34583341-C66DB3E4-28CB-4C17-9CEE-15CFB8743BF7

Q34583341-FAF0C547-30FD-44C2-BC04-89D65EC3DDC2

P304

Q34583341-9A51E27F-5B2E-4C0F-A9E7-3E7F80BB68E1

P31

Q34583341-3CE958F1-D032-4CBB-B471-3D5DACCCF483

P356

Q34583341-3F6A110B-20EE-4369-A4D8-868350920023

P407

Q34583341-63641C98-BA96-44EA-A07A-A7D4269798A6

P433

Q34583341-3FB3B62B-4E46-4FAD-A318-3367513A02FC

P478

Q34583341-7F7C8158-5D58-4F40-AFB8-BC7CD191E46E

P50

Q34583341-A6111F1E-0BF3-4368-BEE8-63E7ECEE93A3

Q34583341-DC609649-B2DA-4AA7-BA4B-0C54DEB1F647

P577

Q34583341-B1193A54-1AA8-4ADF-BB7F-3FF34637F6D1

P5875

Q34583341-B25BD5D1-9F50-4F8E-AB70-1E042936713C

P698

Q34583341-9BDB14FE-34D6-49A3-BE5E-9EE310975178

P921

Q34583341-9AF97855-D0A4-4F3A-A7A0-33ED48988345

Q34583341-E6127FFF-F18B-440B-9477-7EEBDFAE73D4

P932

Q34583341-FC286F23-D1BB-4D89-8188-113CA6DA954F

P356

P1433

P1476

Insulin degludec in type 1 dia ...... compared with insulin glargine

@en

P2093

Anthony P Roberts

http://www.w3.org/2001/XMLSchema#string

Karsten Lyby

http://www.w3.org/2001/XMLSchema#string

Kåre I Birkeland

http://www.w3.org/2001/XMLSchema#string

Lars A Endahl

http://www.w3.org/2001/XMLSchema#string

Luigi F Meneghini

http://www.w3.org/2001/XMLSchema#string

Philip D Home

http://www.w3.org/2001/XMLSchema#string

Robert E Ratner

http://www.w3.org/2001/XMLSchema#string

Thue Johansen

http://www.w3.org/2001/XMLSchema#string

Ulrich Wendisch

http://www.w3.org/2001/XMLSchema#string

P2860

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial.

The barrier of hypoglycemia in diabetes.

Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus.

Hypoglycemia unawareness is associated with reduced adherence to therapeutic decisions in patients with type 1 diabetes: evidence from a clinical audit.

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.

Nocturnal hypoglycaemia in type 1 diabetes--frequency and predictive factors.

Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.

Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study

P304

661-665

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC10-1925

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

J. Hans DeVries

P577

2011-01-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49788191

http://www.w3.org/2001/XMLSchema#string

P698

21270174

http://www.w3.org/2001/XMLSchema#string

P921

type-1 diabetes

P932

3041203

http://www.w3.org/2001/XMLSchema#string